Testicular cancer: Clinical practice guidelines

Robert J. Motzer*, Robert R. Bahnson, Barry Boston, Michael A. Carducci, Mayer Fishman, Steven L. Hancock, Ralph J. Hauke, Gary R. Hudes, Philip Kantoff, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Chris Logothetis, Kim A. Margolin, Bruce G. Redman, Sylvia Richey, Cary N. Robertson, Wolfram E. Samlowski, Joel Sheinfeld, Donald A. Urban

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Ninety five percent of malignant tumors arising in the testes are germ cell tumors (GCTs). Although GCTs are relatively uncommon tumors, comprising only 2% of all human malignancies, they constitute the most common solid tumor in men between 15 and 34. Additionally, the worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of all patients diagnosed with GCT are cured, but a delay in diagnosis can correlate with a higher stage at presentation. Standard therapy has been developed for essentially all stages of management and must be closely followed to ensure the potential for cure.

Original languageEnglish (US)
Pages (from-to)52-76
Number of pages25
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume3
Issue number1
StatePublished - Jan 1 2005

Keywords

  • Alpha-fetoprotein
  • Cisplatin
  • Germ cell tumors
  • Human chorionic gonadotropin
  • Lactate dehydrogenase
  • NCCN Clinical Practice Guidelines
  • Nonseminoma
  • Seminoma
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Testicular cancer: Clinical practice guidelines'. Together they form a unique fingerprint.

Cite this